Loading...
Market
What will be the outcome of Moderna's joint agreement with Mitsubishi Tanabe Pharma by the end of 2025?
2
Resolution / Starting Odds
Launch new mRNA respiratory vaccine • 25%
Expand existing COVID-19 vaccine portfolio • 25%
Both • 25%
Neither • 25%
Official announcements from Moderna or Mitsubishi Tanabe Pharma
Story
US to Pay Moderna $176 Million for Pandemic Flu Vaccine Amid Bird Flu Concerns
Jul 8, 2024, 06:58 PM
The US government has agreed to pay Moderna $176 million to develop a pandemic flu vaccine. This move comes as part of a broader effort to prepare for potential future pandemics, including bird flu. Finland and fourteen other EU countries have also signed up to procure bird-flu vaccines. Additionally, Moderna and Mitsubishi Tanabe Pharma have entered a joint agreement to promote Moderna’s mRNA respiratory vaccine portfolio in Japan, which includes COVID-19 vaccines. Concerns are rising about the H5N2 and H5N1 viruses, with the NIAID involved in related research.
View original story
Similar markets
Effective • 25%
Moderately Effective • 25%
Ineffective • 25%
Halted • 25%
Successful with no major side effects • 25%
Successful with some side effects • 25%
Unsuccessful • 25%
Inconclusive • 25%
Positive • 25%
Negative • 25%
Neutral • 25%
Not Reported • 25%
Continued use without changes • 25%
Usage restrictions for certain age groups • 25%
Temporary suspension • 25%
Permanent ban • 25%
Yes • 50%
No • 50%
Pfizer • 25%
AstraZeneca • 25%
GlaxoSmithKline • 25%
Other • 25%
COVID-19 vaccines • 25%
RSV vaccines • 25%
Other vaccines • 25%
Non-vaccine products • 25%
